AACR Award for Lifetime Achievement in Cancer Research will be presented to Rakesh K. Jain, PhD, Fellow of the AACR Academy, during the AACR Annual Meeting 2025, to be held April 25-30 at the ...

The following is a summary of "Controversial Role Of Cd151 In Different Solid Tumors: Promoter Or Suppressor?,” published in ...

Jennifer Chan, MD, MPH, discussed the recent FDA approval of cabozantinib in pancreatic and extrapancreatic neuroendocrine tumors.

DelveInsight’s, “Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 195+ companies and ...

Neuroendocrine tumors that start in the pancreas tend to be more aggressive and have a poor prognosis.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one ...

Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat ...

Particularly noteworthy among these compounds are 6-gingerol and 6-shogaol, which have been recognized for their potent anticancer properties. These compounds work through several mechanisms, notably ...

Conference Call to discuss Updated Data from Part B of the DeFianCe Study March 26, 2025 8:00 AM ET. Company Participants. Douglas Onsi - President ...

Summit Therapeutics' ivonescimab outperforms Keytruda in Phase 3 lung cancer trials. Crucial Western market approval depends ...